AI Insight
Four children with diffuse intrinsic pontine glioma (DIPG), an aggressive and typically fatal brain cancer, have shown complete remission following treatment with an experimental CAR-T cell immunotherapy. The therapy was designed to target tumor cells while sparing healthy brain tissue. A personalized version of this treatment is currently being tested in additional pediatric patients with similar brain tumors.
Why it matters
DIPG has historically had no effective treatment options, with most patients surviving less than a year after diagnosis. This experimental therapy represents a potential breakthrough in treating one of the most challenging pediatric cancers, offering hope for children with previously untreatable brain tumors.
Understand the Science
An experimental immunotherapy has beaten aggressive brain tumours in a handful of children, and a personalised version is now being tested on more patients
Source: Four children with terminal brain cancer saved by new cell therapy